BioCryst’s Strategic Advancements and Market Potential: A Buy Rating by Serge Belanger

Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating on May 6.

Serge Belanger has given his Buy rating due to a combination of factors that highlight BioCryst’s strategic advancements and market potential. The FDA’s Priority Review for BioCryst’s New Drug Application (NDA) for a pediatric formulation of Orladeyo is a significant milestone. This formulation targets hereditary angioedema (HAE) patients aged 2-11, marking it as the first oral prophylactic therapy for this age group, which could substantially expand the patient base.
Furthermore, BioCryst has already revised its 2025 sales guidance for Orladeyo upwards twice this year, indicating strong market performance and confidence in future profitability. The potential expansion into the pediatric market is not yet factored into the current sales projections, suggesting additional growth opportunities. This strategic move aligns with BioCryst’s goal of achieving $1 billion in global sales by 2029, reinforcing the company’s long-term growth prospects.

According to TipRanks, Belanger is a 2-star analyst with an average return of -0.1% and a 38.63% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, Liquidia Technologies, and BioCryst.

In another report released on May 6, Evercore ISI also maintained a Buy rating on the stock with a $12.00 price target.